At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Trading 06-11 15:12:11 EDT
444.13
+5.10
+1.16%
High448.72Low431.92Vol8.81M
Open438.91D1 Closing439.04Amplitude3.83%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O147.83MT/O Rate--Tradable Shares0.00
P/B2.831519ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
TIPRANKS  ·  06-11 16:31
Analysts Offer Insights on Healthcare Companies: Crispr Therapeutics AG (CRSP) and Hinge Health, Inc. Class A (HNGE)
Intellia Therapeutics shareholders elect Class I directors at annual meeting
Reuters  ·  06-11 04:36
Intellia Therapeutics shareholders elect Class I directors at annual meeting
A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise
Simply Wall St.  ·  06-10 01:30
A Look At Intellia Therapeutics (NTLA) Valuation After Phase 3 HAE Success And Equity Raise
Beam Stockholders Back Board, Leadership at Annual Meeting
TIPRANKS  ·  06-09 05:06
Beam Stockholders Back Board, Leadership at Annual Meeting
Beam Therapeutics shareholders elect Class III directors at annual meeting
Reuters  ·  06-09 04:06
Beam Therapeutics shareholders elect Class III directors at annual meeting
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
THOMSON REUTERS  ·  06-08
Sangamo Therapeutics Announces Exploration of Strategic Alternatives to Maximize Value for Stakeholders
Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next
Simply Wall St.  ·  06-07
Why CRISPR Therapeutics (CRSP) Is Down 7.7% After Major Shelf Filing and Governance Changes – And What's Next
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire  ·  06-06
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Shareholders Approve New Incentive Plan and Governance Measures
TIPRANKS  ·  06-05
Shareholders Approve New Incentive Plan and Governance Measures
CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting
Reuters  ·  06-05
CRISPR Therapeutics shareholders approve 2026 stock option and incentive plan at annual meeting
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
TIPRANKS  ·  06-04
Analysts Are Bullish on Top Healthcare Stocks: Insulet (PODD), Crispr Therapeutics AG (CRSP)
Intellia to present additional Phase 3 HAELO data for lonvo-z in hereditary angioedema at EAACI 2026
Reuters  ·  06-01
Intellia to present additional Phase 3 HAELO data for lonvo-z in hereditary angioedema at EAACI 2026
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
GlobeNewswire  ·  06-01
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift
Simply Wall St.  ·  05-29
Why Intellia Therapeutics (NTLA) Is Up 10.6% After CRISPR Phase III Win And FDA Hold Lift
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
GlobeNewswire  ·  05-29
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire  ·  05-28
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
TIPRANKS  ·  05-28
Editas Medicine preclinical data ‘looks highly supportive,’ says Evercore ISI
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’
TIPRANKS  ·  05-28
TD Cowen remains bullish on Editas Medicine after ‘compelling preclinical data’

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--